Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 16/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 10/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670163 | 0.91 | NPBWR1 (0.53) | NPBWR1MCHR1ALDH1A1NPSR1SCN9A | |
| SCHEMBL4670553 | 0.91 | NPBWR1 (0.56) | NPBWR1MCHR1ALDH1A1NPSR1 | |
| SCHEMBL4939044 | 0.90 | NPBWR1 (0.51) | NPBWR1MCHR1ALDH1A1NPSR1 | |
| SCHEMBL4670155 | 0.90 | NPBWR1 (0.51) | NPBWR1MCHR1ALDH1A1NPSR1 | |
| SCHEMBL4670687 | 0.88 | MCHR1 (0.61) | NPBWR1MCHR1ALDH1A1NPSR1 | |
| SCHEMBL14221012 | 0.87 | NPBWR1 (0.54) | NPBWR1MCHR1ALDH1A1NPSR1 | |
| SCHEMBL14282447 | 0.87 | NPBWR1 (0.50) | NPBWR1MCHR1ALDH1A1NPSR1 | |
| SCHEMBL4649285 | 0.86 | NPBWR1 (0.53) | NPBWR1MCHR1ALDH1A1NPSR1 | |
| SCHEMBL14029986 | 0.85 | NPBWR1 (0.52) | NPBWR1MCHR1ALDH1A1NPSR1 | |
| SCHEMBL4670320 | 0.84 | NPBWR1 (0.57) | NPBWR1MCHR1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497269-B1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | BAYER HEALTHCARE AG (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-7320977-B2 | Fibrotic disorders; disorders characterized by harmful buildup of collagen and/or by excessive lysyl oxidase enzymatic activity | BAYER HEALTHCARE AG (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-05 | — | — | US | disclosed |
| EP-1497269-A1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | Bayer HealthCare AG (DE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003097612-A1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | PIR, TPMT, PNPO | NPBWR1 4199/4885MCHR1 4400/4885ALDH1A1 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.